17 August 2026 | 6:56AM HKT Equity Research JD Health International (6618.HK) 1H26 review and NDR takeaways: Demonstrating strong execution amid regulation uncertainty; 2H26 set to accelerate; Buy 6618.HK 12m Price Target: HK$59.00 Price: HK$39.50 Upside: 49.4% JD Health reported largely inline 1H26 results and mgmt's refreshed FY26 guidance reiterates our view that JDH is demonstrating strong execution capabilities and further gaining share across segments, despite the nutrition/GLP related regulation unce ...